Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTI 0102

Drug Profile

TTI 0102

Alternative Names: cysteamine-R-pantetheine disulfide; TTI-0102

Latest Information Update: 02 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thiogenesis Therapeutics
  • Class Anti-inflammatories; Antivirals; Small molecules; Thiosulfates
  • Mechanism of Action Antioxidants; Inflammation mediator inhibitors; Metabolism-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections; Traumatic brain injuries

Most Recent Events

  • 28 Jan 2022 Thiogenesis Therapeutics plans a phase II trial for COVID-2019 infections (In adults, In the elderly) in June 2022 (PO, Powder) (NCT05212662)
  • 09 Feb 2021 Preclinical trials in COVID-2019 infections in USA (PO)
  • 09 Feb 2021 Thiogenesis Therapeutics plans a phase I trial for COVID-2019 infections (In volunteers) in Australia (PO,Powder) (ACTRN12621000131853p)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top